NCT07295496Active, not recruitingPhase 1
A Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Anti-IL-RAP Humanized Monoclonal Antibody Injection in Chinese Subjects
Innovent Biologics (Suzhou) Co. Ltd.1 site in 1 country64 target enrollmentStarted: December 8, 2025Last updated:
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare (Part B)
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects are eligible for the study if they meet all of the following Inclusion Criteria:
- •Age ≥18 years of age, male or female;
- •Body mass index (BMI) 18-26 kg/m2 (inclusive) for Part A healthy subjects and BMI 18-40 kg/m2 (inclusive) for Part B acute gout flare subjects; Part B acute gout flare subjects also needed to meet the following criteria
- •Meet ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout;
- •Other inclusion criteria set by protocol
Exclusion Criteria
- •Subjects meeting any of the following criteria are not eligible to attend this clinical study:
- •Difficulties in venous blood collection or a history of dizziness when encountering blood or needles;
- •Have received an experimental agent within 1 month or 5 times half-life (whichever is longer) prior;
- •Have live or attenuated vaccination in the 3 months before randomization or plan to receive that during this trial;
- •Blood donation or blood loss of more than 400 mL within 8 weeks before the screening;
- •Have a history of severe infection, severe trauma, or major surgical procedures within 6 months before the screening;
- •History of malignancy;
- •Female during pregnancy or lactation;
- •Have a history of drug abuse, drug dependence, or a positive result in a drug screen within 12 months before the screening;
- •Has a history of neuropsychiatry or any other disease/ailment that is unsuitable for this clinical trial at the discretion of the Investigator;
- •Part B acute gout flare subjects also needed to exclude the following criteria:
- •Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout);
- •Infection/septic arthritis, or other acute inflammatory arthritis;
- •Other exclusion criteria set by protocol
Arms & Interventions
IBI3011
Active Comparator
IBI3011 group
Intervention: IBI3011 (Drug)
Placebo
Placebo Comparator
IBI3011 placebo group
Intervention: IBI3011 Placebo (Drug)
Outcomes
Primary Outcomes
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: 12 week
To investigate the safety characteristics.
Secondary Outcomes
- Immunogenic outcome(12 week)
- AUC(12 Week)
- Cmax(12 Week)
- CL or CL/F(12 Week)
- V or V/F(12 Week)
- t1/2(12 Week)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyNCT07282652Peking Union Medical College Hospital12
Recruiting
Phase 1
Safety and Pharmacokinetics Study of BCD101 in Healthy VolunteersNCT07282145Bichedam Co., Ltd.56
Not yet recruiting
Phase 1
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological MalignanciesNCT07294300Qilu Pharmaceutical Co., Ltd.124
Recruiting
Phase 1
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsCystic FibrosisNCT07283770Vertex Pharmaceuticals Incorporated136